Ibrexafungerp is an antifungal agent and the first representative of a novel class of structurally-distinct glucan synthase inhibitors, triterpenoids. Dr Martin Hoenigl (Professor, Translational Mycology, Medical University of Graz, Austria) discusses the ongoing Phase III FURI study investigating oral ibrexafungerp for the treatment of patients with severe fungal infections who are either intolerant to standard antifungal therapy or experience refractory fungal infections despite treatment.
The presentation entitled: ‘Oral ibrexafungerp outcomes by fungal disease in patients from 4th interim analysis of a phase III open-label study (FURI)’ was presented at the 32nd European Congress of Clinical Microbiology & Infectious Diseases (ECCMID), 23-26 May 2022.
Questions:
- Could you give us a brief overview of the clinical burden of fungal pathogens and the unmet needs in their treatment?
- What is the rationale for the use of oral ibrexafungerp for the treatment of patients who are intolerant of or with fungal disease refractory to standard antifungal therapy?
- What were the aims, design and eligibility criteria of the FURI study?
- What have been the interim findings of this study?
- Which patients are most likely to benefit from ibrexafungerp treatment?
Disclosures: Martin Hoenigl receives grant/research support from Gilead, Scynexis, Pfizer, Astellas, MSD, Euroimmun, and F2G.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Katey Gabrysch.
